-
ESTIMATING PRODUCTIVITY LOSS FROM A SOCIETAL PERSPECTIVE: A PRACTICAL FRAMEWORK USING U.S. PUBLIC-USE DATA
Mar 18, 2026, 21:38 PM -
CULTURAL ADAPTATION AND LINGUISTIC VALIDATION OF THE CANCER AWARENESS MEASURE FOR INDIVIDUALS WITH INTELLECTUAL DISABILITIES IN HUNGARY
Mar 18, 2026, 21:38 PM -
COST-EFFECTIVENESS OF REMIBRUTINIB FOR MODERATE TO SEVERE CHRONIC SPONTANEOUS URTICARIA IN THE U.S.
Mar 18, 2026, 21:38 PM -
COMPARISON OF ISCHEMIC STROKE INCIDENCE RATES IN HUNGARY AND EUROPE BASED ON DATA FROM THE GLOBAL BURDEN OF DISEASE STUDY
Mar 18, 2026, 21:38 PM -
FEASIBILITY ASSESSMENT OF INDIRECT TREATMENT COMPARISON BETWEEN OFF-LABEL RITUXIMAB AND NOVEL TREATMENTS IN PATIENTS WITH WARM AUTOIMMUNE HEMOLYTIC ANEMIA
Mar 18, 2026, 21:38 PM -
REAL-WORLD TREATMENT PATTERNS AND EFFICACY OF FIRST-LINE THERAPIES IN PATIENTS WITH MET EXON 14 SKIPPING-MUTATED NON-SMALL CELL LUNG CANCER
Mar 18, 2026, 21:38 PM -
ADHERENCE AND PERSISTENCE IN US REAL-WORLD NEW PREP USERS: CABOTEGRAVIR VS EMTRICITABINE/TENOFOVIR ALAFENAMIDE
Mar 18, 2026, 21:38 PM -
GENERATIVE AI IN HEALTH ECONOMIC MODELLING: A TARGETED REVIEW OF EMERGING APPLICATIONS AND METHODOLOGICAL GAPS
Mar 18, 2026, 21:38 PM -
DETERMINING AN ECONOMICALLY JUSTIFIABLE PRICE FOR TRONTINEMAB IN EARLY ALZHEIMER’S DISEASE
Mar 18, 2026, 21:38 PM -
EVALUATING INITIAL MEDICATION ADHERENCE THRESHOLDS AS PREDICTORS OF CONTINUATION ADHERENCE AMONG PATIENTS WITH MAJOR DEPRESSIVE DISORDER: A CLAIMS-BASED ANALYSIS
Mar 18, 2026, 21:38 PM -
THE IMPACT OF MEDICATION ADHERENCE ON REAL-WORLD CLINICAL AND ECONOMIC OUTCOMES: A SCOPING REVIEW OF REAL-WORLD EVIDENCE
Mar 18, 2026, 21:38 PM -
SOCIODEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF LATANOPROSTENE BUNOD INITIATORS AMONG MEDICARE FEE-FOR-SERVICE PATIENTS WITH OPEN ANGLE GLAUCOMA AND OCULAR HYPERTENSION
Mar 18, 2026, 21:38 PM -
REAL WORLD EVIDENCE FOR LABEL EXPANSION: IDENTIFYING OFF-LABEL USE TRENDS IN THE HOSPITAL SETTING
Mar 18, 2026, 21:38 PM -
THE ACCESSIBILITY OF ANTI-CANCER DRUGS IN CHINA'S URBAN CUSTOMIZED COMMERCIAL MEDICAL INSURANCE
Mar 18, 2026, 21:38 PM -
A LONG-TERM COST-EFFECTIVENESS MODELLING STUDY OF SEMAGLUTIDE FOR THE TREATMENT OF ADULTS WITH OVERWEIGHT AND OBESITY IN CHINA
Mar 18, 2026, 21:38 PM -
THE IMPACT OF GLYCEMIC CONTROL AND MEDICATION ADHERENCE ON HOSPITALIZATION RISK IN TYPE 2 DIABETES: A LONGITUDINAL REAL-WORLD EVIDENCE STUDY FROM THE LITHUANIAN NATIONAL HEALTH INSURANCE FUND ADMINISTRATIVE DATA
Mar 18, 2026, 21:38 PM -
ENHANCING ONCOLOGY REAL WORLD DATA QUALITY THROUGH CLINICALLY RELEVANT EDIT CHECKS IN A LARGE US COMMUNITY ONCOLOGY DATABASE
Mar 18, 2026, 21:38 PM -
MEDICARE COST OF MINIMALLY INVASIVE BIOMARKER TESTS TO DETECT DONOR-DERIVED CELL-FREE DNA (DD-CFDNA)
Mar 18, 2026, 21:38 PM -
WHEN THE TAIL WAGS THE DOG: RETHINKING PARTITIONED SURVIVAL MODELLING IN ONCOLOGY
Mar 18, 2026, 21:38 PM -
COST-UTILITY ANALYSIS OF SACITUZUMAB TIRUMOTECAN (SAC-TMT) IN PREVIOUSLY TREATED EGFR-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS: A CHINESE HEALTHCARE SYSTEM PERSPECTIVE
Mar 18, 2026, 21:38 PM
